MARKET

APTO

APTO

Aptose
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.82
+0.16
+2.83%
Opening 10:14 01/28 EST
OPEN
5.74
PREV CLOSE
5.66
HIGH
5.87
LOW
5.71
VOLUME
62.28K
TURNOVER
--
52 WEEK HIGH
6.66
52 WEEK LOW
1.570
MARKET CAP
442.94M
P/E (TTM)
-10.3430
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of APTO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

APTO News

  • The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
  • Benzinga.6d ago
  • Is the Options Market Predicting a Spike in Aptose (APTO) Stock?
  • Zacks.01/17 13:44
  • Piper Sandler Initiates Coverage On Aptose Biosciences with Overweight Rating, Announces $10 Price Target
  • Benzinga.01/09 15:48
  • UBS upgrades Madrigal Pharma in premarket analyst action
  • Seeking Alpha - Article.01/09 13:10

More

Industry

Biotechnology & Medical Research
+1.29%
Pharmaceuticals & Medical Research
+0.62%

Hot Stocks

Name
Price
%Change

About APTO

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
More

Webull offers Aptose Biosciences Inc (APTO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.